1312478-47-9

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl (±)-4-bromo-2-methyl-2-(methylsulfonyl)butanoate is used as a key intermediate in the synthesis of pyridine methylsulfone hydroxamate LpxC inhibitors. These inhibitors play a crucial role in treating bacterial infections by targeting the LpxC enzyme, which is essential for the synthesis of lipid A, a component of the bacterial cell wall. By inhibiting LpxC, these compounds can effectively disrupt bacterial cell wall synthesis, leading to the death of the bacteria and helping to combat infections.

Upstream product

• 73017-82-0 Ethyl α-(methylsulfonyl)propionate 
• 106-93-4 ethylene dibromide 
• 535-13-7 2-chloro-propanoic acid, ethyl ester 

Downstream Products

• 1312478-87-7 ethyl 2-methyl-2-(methylsulfonyl)-4-(2-oxo-4-phenylpyridin-1(2H)-yl)butanoate 
• 1358778-53-6 (2R)-2-methyl-2-(methylsulfonyl)-4-(6-oxo-4-phenylpyridazin-1(6H)-yl)butanoic acid 
• 1358778-50-3 (2R)-2-methyl-2-(methylsulfonyl)-4-(6-oxo-4-phenylpyrimidin-1(6H)-yl)butanoic acid 
• 1358778-46-7 (2R)-2-methyl-2-(methylsulfonyl)-4-(2-oxo-4-phenylpyrimidin-1(2H)-yl)butanoic acid 
• 1312479-50-7 ethyl (2R)-4-(5-fluoro-2-oxo-4-phenylpyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid 
• 1358778-43-4 (2R)-2-methyl-4-(6-methyl-2-oxo-4-phenylpyridin-1(2H)-yl)-2-(methylsulfonyl)butanoic acid 
• 1358778-39-8 (2R)-2-methyl-4-(5-methyl-2-oxo-4-phenylpyridin-1(2H)-yl)-2-(methylsulfonyl)butanoic acid 
• 1358778-35-4 (2R)-2-methyl-4-(3-methyl-2-oxo-4-phenylpyridin-1(2H)-yl)-2-(methylsulfonyl)butanoic acid 
• 1312478-90-2 ethyl (2R)-2-methyl-2-(methylsulfonyl)-4-(2-oxo-4-phenylpyridin-1(2H)-yl)butanoic acid 
• 1358778-54-7 (2R)-2-methyl-2-(methylsulfonyl)-4-(6-oxo-4-phenylpyridazin-1(6H)-yl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
• 1381755-56-1 (2R)-2-methyl-2-(methylsulfonyl)-4-(6-oxo-4-phenylpyrimidin-1(6H)-yl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
• 1358778-47-8 (2R)-2-methyl-2-(methylsulfonyl)-4-(2-oxo-4-phenylpyrimidin-1(2H)-yl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
• 1312479-51-8 (2R)-4-(5-fluoro-2-oxo-4-phenylpyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
• 1381755-55-0 C₂₃H₃₀N₂O₆S 

Relevant academic research and scientific papers

FLUORO-PYRIDINONE PHOSPHATES AND BORONATES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae (I), (II) and (III) wherein Q is selected from the group consisting of –P(O)(OH)2, –P(O)(OH)(O-M+), –P(O)(O-M+)2/

PYRIDINONE AND PYRIMIDINONE PHOSPHATES AND BORONATES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to new pyridinone or pyrimidinone hydroxamic acid phosphates of Formula (1 ) and boronates of Formula (2), stereoisomers thereof; wherein Q is selected from the group consisting of -P(0)(OH)2, -P(0)(OH)(0"M+), - P(0)(0"M+)2 and -P(0)(0")2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation; X is CH or N; and Z is as defined herein; and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS

The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious Gram-negative infections

The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.

FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

IMIDAZOLE, PYRAZOLE, AND TRIAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as Lpx C inhibitors and, more specifically, their use to treat bacterial infections.

N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. Formula (I).